SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 30, 2009

 

ARQULE, INC.

(Exact Name of Issuer as Specified in Charter)

 

Delaware

 

000-21429

 

04-3221586

(State or other jurisdiction

 

(Commission File Number)

 

(I.R.S. Employer

of incorporation)

 

 

 

Identification No.)

 

19 Presidential Way
Woburn, MA

(Address of principal executive offices)

 

01801

(Zip code)

 

(781) 994-0300

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Section 1— Registrant’s Business and Operations

 

Item 1.02 Termination of a Material Definitive Agreement.

 

As previously reported, ArQule, Inc. (the “Registrant”) entered into a strategic alliance agreement with F. Hoffman-La Roche Ltd. and Hoffman-La Roche Inc. (collectively, “Roche”) dated April 1, 2004.  On December 19, 2008, the Registrant announced that Roche had notified the Registrant of its intention not to exercise its option to license the Registrant’s E2F-1 program under the agreement.  On January 30, 2009, the Registrant notified Roche that the agreement had been terminated in accordance with its terms. As a result, all rights and licenses granted by the Registrant to Roche under the agreement also terminated and reverted to the Registrant.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ARQULE, INC.

 

(Registrant)

 

 

 

/s/ Peter S. Lawrence

 

Peter S. Lawrence

 

President and Chief Operating Officer

 

 

February 4, 2009

 

2